Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6400231 | 1.00 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL13851870 | 0.98 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL4145834 | 0.98 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL4145829 | 0.98 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| Tert-Butylamine SCHEMBL4147578 | 0.89 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| Tert-Butylamine SCHEMBL4147580 | 0.89 | GRIK1 (0.32) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| Potassium Ion SCHEMBL6395315 | 0.78 | CA4 (0.33) | — | |
| SCHEMBL5364063 | 0.78 | MGAM (0.37) | ALDH1A1 | |
| Potassium Ion SCHEMBL6395320 | 0.78 | CA4 (0.33) | — | |
| SCHEMBL5364066 | 0.78 | MGAM (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891059-B2 | Asymmetric synthesis of pregabalin | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1250311-B1 | ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | BURK MARK JOSEPH (US) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212290-A1 | Asymmetric synthesis of pregabalin | GABRA5, GABRA6, GABRE | GRIK1 59/4885GRIA2 45/4885GRIA4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.